Drugs / Abivertinib

Trials 13 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 14 trials
Phase 1 NCT03060850 Mar 2017 → Dec 2019 B-cell non-Hodgkin lymphoma Hangzhou ACEA Pharmaceutical Research Co., Ltd. Unknown No outcome recorded
Phase 1 NCT03053219 Nov 2016 → Jul 2018 non-small cell lung carcinoma Hangzhou ACEA Pharmaceutical Research Co., Ltd. Completed No outcome recorded
Phase 1 NCT03001609 Nov 2016 → Aug 2017 non-small cell lung carcinoma Hangzhou ACEA Pharmaceutical Research Co., Ltd. Completed No outcome recorded
Phase 1 NCT02448251 May 2015 → Oct 2019 non-small cell lung carcinoma ACEA Therapeutics, Inc. Terminated No outcome recorded
Phase 1/22 trials
Phase 1/2 NCT02330367 Jan 2015 → Dec 2022 non-small cell lung carcinoma Hangzhou ACEA Pharmaceutical Research Co., Ltd. Unknown No outcome recorded
Phase 1/2 NCT02274337 Sep 2014 → Jun 2017 non-small cell lung carcinoma Sun Yat-sen University Unknown No outcome recorded
Phase 25 trials
Phase 2 NCT05361915 Sep 2025 → Jan 2028 metastatic prostate carcinoma Sorrento Therapeutics, Inc. Suspended No outcome recorded
Phase 2 NCT04528667 Jan → Aug 2021 COVID-19 Sorrento Therapeutics, Inc. Completed No outcome recorded
Phase 2 NCT04440007 Oct 2020 → Jul 2021 COVID-19 Sorrento Therapeutics, Inc. Completed No outcome recorded
Phase 2 NCT03574402 Jul 2018 → Dec 2022 non-small cell lung carcinoma Guangdong Association of Clinical Trials Unknown No outcome recorded
Phase 2 NCT03300115 May 2017 → Jun 2019 non-small cell lung carcinoma Hangzhou ACEA Pharmaceutical Research Co., Ltd. Unknown No outcome recorded
Phase 32 trials
Phase 3 NCT03856697 Mar 2019 → Mar 2022 non-small cell lung carcinoma Hangzhou ACEA Pharmaceutical Research Co., Ltd. Unknown No outcome recorded
Phase 3 NCT03058094 Dec 2018 → Dec 2019 non-small cell lung carcinoma Hangzhou ACEA Pharmaceutical Research Co., Ltd. Withdrawn No outcome recorded

Evidence & citations 19 cited values

Every value below carries the sentence it was read from. 14 sources stand behind the page.

FieldValueCited text
Known as Abivertinib ClinicalTrials.gov intervention name — accepted as the source's own label NCT05361915
2

NCT04440007

NCT03856697

Known as A-610MA ChEMBL registry synonym — accepted as the source's own label CHEMBL4297865
Known as A610 ChEMBL registry synonym — accepted as the source's own label CHEMBL4297865
Known as ABIVERTINIB MALEATE ChEMBL registry synonym — accepted as the source's own label CHEMBL4297865
Known as Abivertinib maleate dihydrate ChEMBL registry synonym — accepted as the source's own label CHEMBL4297865
Known as AC0010 ClinicalTrials.gov intervention name — accepted as the source's own label NCT03300115
5

NCT02330367

NCT03001609

NCT03058094

NCT03053219

NCT02274337

Known as Ac0010 maleate dihydrate ChEMBL registry synonym — accepted as the source's own label CHEMBL4297865
Known as AC0010MA ClinicalTrials.gov intervention name — accepted as the source's own label NCT02448251
1

NCT03060850

Known as ACEA-100610MA ChEMBL registry synonym — accepted as the source's own label CHEMBL4297865
Known as ACEA100610 ChEMBL registry synonym — accepted as the source's own label CHEMBL4297865
Known as Avitinib ChEMBL registry synonym — accepted as the source's own label CHEMBL4297865
Known as Avitinib Maleate ClinicalTrials.gov intervention name — accepted as the source's own label NCT03574402
Known as EX-ACEA-0010MA ChEMBL registry synonym — accepted as the source's own label CHEMBL4297865
Known as EX-ACEA0010 ChEMBL registry synonym — accepted as the source's own label CHEMBL4297865
Known as STI-5656 ClinicalTrials.gov intervention name — accepted as the source's own label NCT04528667
Action Inhibit “selectively suppress the activities of EGFR tyrosine kinase phosphorylation” NCT02274337
Modality Small molecule “AC0010 is a novel, potent, small molecule irreversible tyrosine kinase inhibitor (TKI)” NCT02330367
Route Oral oral AC0010” NCT02330367
Target EGFR “selectively suppress the activities of EGFR tyrosine kinase phosphorylation” NCT02274337